How a Most Unlikely Drug Changed the Outcome of Pulmonary Arterial Hypertension.

Summary: Imagine a medicine so demanding it requires a pump connected to your veins 24 hours a day, yet it is so effective it remains a miracle worker. That is the story of Epoprostenol. Discovered in the 1970s, this potent blood vessel widener changed the game for Pulmonary Arterial Hypertension (PAH), a deadly lung condition. Before its FDA approval in 1995, patients had virtually no hope. Today, despite the existence of newer, easier-to-take pills, this complex "high-maintenance" IV therapy remains the gold standard for survival and effectiveness nearly 30 years later.